Ticagrelor

Introduction Overview

Generic Name

ticagrelor

Brand Name

Brilinta

Dosage Form

oral tablet (60 mg; 90 mg)

Drug Class

Platelet aggregation inhibitors

Pharmacokinetics

Absorption:
Ticagrelor is rapidly and extensively absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Cmax) are typically reached within 1.5 hours post-dose. The absolute bioavailability of ticagrelor oral tablets is approximately 36%, indicating moderate systemic exposure after oral dosing. The absorption is not significantly affected by food intake, allowing administration with or without meals, which facilitates patient compliance. Pharmacokinetic studies have shown consistent absorption profiles in healthy individuals and patients with cardiovascular disease.

Distribution:
Ticagrelor exhibits extensive plasma protein binding, primarily binding to albumin at approximately 99.8%, ensuring a high degree of drug transport in the bloodstream. The volume of distribution (Vd) is moderate, approximately 87 liters, indicative of moderate tissue penetration. Ticagrelor and its active metabolite distribute into platelets and plasma, targeting P2Y12 receptors effectively. It does not accumulate extensively in erythrocytes or adipose tissues. Distribution is influenced by plasma protein levels, but clinical significance in altered states is minimal.

Metabolism:
Ticagrelor undergoes extensive hepatic metabolism predominantly via cytochrome P450 enzyme CYP3A4 and to a lesser extent CYP3A5. The primary metabolic pathway generates an active metabolite, AR-C124910XX, which exhibits similar potency to the parent compound. This metabolite contributes significantly to overall antiplatelet activity. Since CYP3A4 is involved, co-administration with strong inhibitors or inducers of this enzyme can alter plasma levels, impacting efficacy and safety. Ticagrelor is not a prodrug; its direct activity offers rapid onset of action compared to thienopyridines.

Elimination:
The elimination of ticagrelor and its active metabolite occurs primarily via hepatic pathways into the feces (about 57%), with renal excretion accounting for approximately 26%. Ticagrelor has a terminal half-life of approximately 7 to 9 hours, allowing twice-daily dosing. The active metabolite has a similar half-life, prolonging the antiplatelet effect. Clearance is not significantly affected by mild to moderate renal impairment but has not been extensively studied in severe renal dysfunction. Hepatic impairment can affect metabolism and clearance, warranting caution in such populations. The drug does not accumulate significantly with repeated dosing due to its half-life and dosing schedule.

Dosage Forms

Available Dosage Forms:
Ticagrelor is available as oral tablets in two strengths: 60 mg and 90 mg. These tablets are film-coated for ease of swallowing. The tablets can be taken whole or, if swallowing is difficult, may be crushed and mixed with water for immediate consumption to ensure bioavailability is not compromised.

Dosages for Adults and Adolescents:
The standard recommended dosage for adults with acute coronary syndromes or recent myocardial infarction typically involves a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily. For secondary prevention in patients with a history of myocardial infarction, a maintenance dose of 60 mg twice daily may be employed, often alongside low-dose aspirin (75-100 mg daily). Use in adolescent populations has not been established and is generally not recommended.

Specific Patient Populations:
Dosage adjustments in patients with renal impairment are not usually required since ticagrelor clearance is not significantly affected. However, caution is recommended in severe hepatic impairment as metabolism may be compromised. Elderly patients usually tolerate standard dosing but increased bleeding risk necessitates careful monitoring. Use in pregnancy and lactation is not advised due to insufficient safety data. Patients with a history of bleeding disorders or recent stroke require individualized dosing consideration and risk-benefit assessment.

Clinical Guidelines:
It is critical to co-administer ticagrelor with low-dose aspirin, avoiding higher aspirin doses (>100 mg daily) as they may diminish ticagrelor's efficacy. Therapy duration typically extends from 6 to 12 months post-stenting or heart attack but may be tailored based on clinical risk factors, ischemic risk, and bleeding risk. Preoperative management guidelines recommend discontinuing ticagrelor approximately 5 days before surgery to minimize bleeding complications.

Mechanism Of Action

Ticagrelor functions as a reversible, direct-acting antagonist of the platelet P2Y12 adenosine diphosphate (ADP) receptor. By binding to this receptor, ticagrelor inhibits ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, preventing platelet aggregation, a crucial step in thrombus formation. This blockade diminishes platelet activation and aggregation, thereby reducing the risk of arterial thrombosis that underlies myocardial infarction and stroke.

Unlike thienopyridine P2Y12 inhibitors such as clopidogrel and prasugrel, which require hepatic bioactivation to active metabolites and bind irreversibly, ticagrelor is an active drug that exerts its effect quickly without metabolic conversion and binds reversibly. This reversible binding results in a more rapid onset and offset of action, enabling more flexible platelet function recovery.

Ticagrelor also increases extracellular adenosine concentrations by inhibiting cellular reuptake via equilibrative nucleoside transporter-1 (ENT1). Elevated adenosine levels may confer additional cardioprotective effects, including vasodilation, anti-inflammatory actions, and improved myocardial perfusion, potentially contributing to the observed clinical benefits beyond platelet inhibition.

Clinical studies have demonstrated that ticagrelor provides superior platelet inhibition and reduces cardiovascular event rates compared with clopidogrel in patients with acute coronary syndrome. This efficacy is attributed to more complete and consistent P2Y12 receptor inhibition, faster onset, and reversible binding dynamics. The dual mechanism involving both P2Y12 antagonism and adenosine modulation represents a novel pharmacologic profile within antiplatelet therapy.

Pharmacological Actions

Reversible inhibition of the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation.
Rapid onset of antiplatelet action due to direct activity without requiring metabolic activation.
Increase of extracellular adenosine levels through inhibition of ENT1, contributing to vasodilation and potential cardioprotection.
Reduction in thrombosis risk by preventing arterial clot formation in coronary, cerebral, and peripheral arteries.
Superior potency and more consistent platelet inhibition compared to thienopyridines like clopidogrel.
Moderate plasma protein binding ensuring effective systemic distribution.
Dual effects on platelet function and vascular tone via adenosine modulation.
Reversible binding allows for faster recovery of platelet function after discontinuation.
Synergistic effect when used concomitantly with low-dose aspirin for enhanced antithrombotic therapy.
Minimal direct effect on cyclooxygenase or other platelet pathways, conferring selectivity.
Favorable pharmacokinetic profile allowing twice-daily dosing for steady antiplatelet effect.
Active metabolite formation that also contributes to overall antiplatelet activity.
Potential anti-inflammatory effects mediated by adenosine receptor activities.
Influences on myocardial blood flow and potential reduction in ischemic injury.
Reduced variability in response compared to prodrug P2Y12 inhibitors.

Therapeutic Or Clinical Uses

Prevention of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) including unstable angina and non-ST elevation and ST elevation myocardial infarction.
Reduction of the risk of myocardial infarction, stroke, and cardiovascular death in patients with a history of heart attack or established coronary artery disease.
Prevention of thrombotic complications in patients undergoing percutaneous coronary intervention with stent placement.
Secondary prevention of ischemic events in patients with peripheral arterial disease and cerebrovascular disease.
Reduction of stroke and death risk in adults with reduced blood flow to the brain due to arterial obstruction.
Adjunct therapy with low-dose aspirin to enhance antiplatelet efficacy and reduce mortality in cardiovascular disease.
Use in patients with decreased blood flow to the heart to prevent first cardiovascular events.
Management of patients requiring long-term antiplatelet therapy after acute cardiovascular events.
Alternative P2Y12 inhibitor in patients with poor response to clopidogrel.
Use in high-risk patients with diabetes mellitus and acute coronary syndrome to reduce adverse events.
Treatment in post-acute coronary syndrome patients to limit recurrent ischemia and revascularization procedures.
Use in patients not suitable for prasugrel due to safety or tolerance issues.
Prevention of stent thrombosis following placement of drug-eluting or bare-metal stents.
Potential off-label uses under clinical investigation for thrombotic disorders with platelet hyperactivity.
Integration into dual antiplatelet therapy protocols to optimize clinical outcomes in cardiovascular disease.

Side Or Adverse Effects

Hemorrhagic events including increased risk of bleeding from various sites (gastrointestinal, intracranial, genitourinary).
Dyspnea characterized by shortness of breath which can range from mild to severe and may require medical evaluation.
Bradyarrhythmias such as slow heart rate documented in some patients, sometimes necessitating monitoring or intervention.
Nosebleeds (epistaxis), prolonged bleeding from minor cuts, and easy bruising.
Gastrointestinal disturbances including nausea and diarrhea.
Hypersensitivity reactions including rash, urticaria, and rare anaphylaxis.
Elevated uric acid levels, potentially disrupting gout management.
Transient increases in serum creatinine and hepatic enzymes.
Cough and respiratory symptoms possibly related to adenosine effects.
Headache, dizziness, and fatigue as neurological side effects.
Rare reports of thrombocytopenia or neutropenia.
Black, tarry stools or vomiting blood indicating gastrointestinal bleeding.
Red or pink discoloration of urine due to hematuria.
Potential bleeding during surgical or dental procedures, requiring cessation beforehand.
Rare but serious bleeding in the brain or other critical sites.

Precautions

Do not use in patients with active pathological bleeding or history of intracranial hemorrhage.
Use caution in patients with increased bleeding risk such as those with peptic ulcers or bleeding disorders.
Avoid abrupt discontinuation to prevent rebound thrombotic events; consult physician before stopping.
Monitor for signs of bleeding including unusual bruising, bleeding gums, or blood in stools or urine.
Inform healthcare providers of ticagrelor use prior to surgeries or invasive procedures to manage bleeding risk.
Exercise caution in patients with impaired hepatic function due to altered drug metabolism.
Be vigilant in patients with asthma, COPD, or other respiratory conditions as dyspnea may worsen.
Ticagrelor may interfere with platelet function tests; inform laboratory personnel before testing.
Avoid concomitant use of strong CYP3A4 inhibitors or inducers to prevent altered drug exposure.
Limit aspirin to low-dose regimens (75-100 mg daily) when combined with ticagrelor to maintain efficacy and safety.
Caution when co-administering other anticoagulants or antiplatelet drugs due to additive bleeding risks.
Consider adjusted use or avoid in elderly patients with comorbidities that increase bleeding likelihood.
Pregnancy and breastfeeding contraindications due to insufficient safety data; discuss alternative therapies.
Advise patients to avoid activities with risk of trauma or injury that could provoke bleeding.
Regularly assess renal and liver function during long-term therapy to detect adverse biochemical changes.

Warnings

Avoid use in patients with active bleeding or history of intracranial hemorrhage due to risk of fatal bleeding.
Discontinue prior to major surgery (at least 5 days) to reduce bleeding complications; follow physician guidance.
Serious bleeding events can be life-threatening including gastrointestinal hemorrhage and intracranial bleeding.
Concomitant use of ticagrelor and NSAIDs or other drugs increasing bleeding risk requires caution.
Do not abruptly stop ticagrelor without medical advice to prevent increased cardiovascular event risk.
Inform patients to seek emergency care if bleeding cannot be controlled or symptoms like unusual bruising occur.
Use with caution in patients with severe hepatic impairment due to potentially increased drug exposure.
Monitor for dyspnea that may spontaneously resolve; if persistent or severe, consider discontinuation.
Drug interactions with CYP3A4 inhibitors (e.g., ketoconazole) may increase bleeding risk by raising ticagrelor levels.
Be aware of potential increased uric acid levels that may precipitate gout in susceptible individuals.
Avoid high doses of aspirin as they may reduce ticagrelor’s antiplatelet efficacy.
Advise against use during pregnancy and breastfeeding due to unknown safety and potential adverse effects.
Precaution in patients with history of asthma or chronic obstructive pulmonary disease due to respiratory side effects.
Potential false results in platelet function testing; inform laboratory staff to adjust testing methods.
Inform patients regarding risk factors and signs of bleeding and importance of adherence to prescribed doses.

Contraindication

Known hypersensitivity or allergy to ticagrelor or any components of the formulation.
Active pathological bleeding such as peptic ulcer bleeding or intracranial hemorrhage.
History of intracranial hemorrhage, including hemorrhagic stroke or cerebral vascular malformations.
Concurrent use of strong CYP3A4 inhibitors that could significantly increase ticagrelor plasma concentration.
Patients requiring urgent surgery where cessation of antiplatelet therapy is not feasible or safe.
Use in combination with higher doses of aspirin (>100 mg/day) that decrease ticagrelor efficacy.
Severe hepatic impairment associated with coagulopathy and risk of bleeding.
Patients with severe bleeding disorders or coagulation abnormalities that predispose to bleeding.
Children and adolescents due to lack of safety and efficacy data in these populations.
Pregnant and breastfeeding women due to unknown fetal and neonatal safety.
Use with other potent antiplatelet or anticoagulant therapies without medical supervision.
Individuals with active or recent major surgery risks where bleeding control is compromised.
Uncorrected bleeding ulcers or gastrointestinal lesions at risk of hemorrhage.
Patients undergoing thrombolytic therapy where bleeding risk is enhanced.
Patients with thrombocytopenia or severe anemia attributable to bleeding risks.

Drug Interactions

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increases ticagrelor plasma levels, heightening bleeding risk.
CYP3A4 inducers (e.g., rifampin, phenytoin) can reduce ticagrelor efficacy by decreasing its plasma concentration.
Increased bleeding risk when combined with other antiplatelet agents such as aspirin and clopidogrel.
Use with anticoagulants (e.g., warfarin, direct oral anticoagulants) potentiates bleeding risk requiring careful monitoring.
Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen may increase bleeding risk when co-administered.
Opioid medications may have pharmacodynamic interactions impacting patient monitoring but no direct PK effects.
Antifungal agents like voriconazole may alter ticagrelor metabolism via CYP3A4 inhibition.
Antiviral drugs used for HIV/AIDS treatment (e.g., ritonavir) may interact through CYP3A4 modulation affecting ticagrelor plasma levels.
Some cholesterol-lowering statins metabolized by CYP3A4 may have altered pharmacokinetics in combination with ticagrelor.
Seizure medications such as carbamazepine induce CYP3A4 and may reduce ticagrelor effectiveness.
Tuberculosis medications, including rifampin, act as strong CYP3A4 inducers and can decrease ticagrelor anticoagulant activity.
Combination with herbs and supplements like St. John's Wort may reduce ticagrelor efficacy via enzyme induction.
Potential additive effects with other platelet function inhibitors may increase bleeding risk.
Co-administration with aspirin exceeding recommended doses (>100 mg) may diminish antiplatelet effect.
Laboratory interference: ticagrelor may alter platelet function assay results, impacting diagnostic interpretation.

Preparations Of The Drug

Film-coated oral tablets available in two strengths: 60 mg and 90 mg.
Tablets designed for oral administration, with option for crushing and suspending in water for patients with swallowing difficulties.
Packaging includes blister packs and bottles with child-resistant closures to ensure dose accuracy and safety.
Stability maintained at room temperature away from excessive moisture and heat.
Formulations do not contain excipients commonly associated with significant allergic reactions.
Available as branded product Brilinta with standardized dosing to minimize hazards.
No widespread generic formulations currently approved; branded drug predominant in clinical use.
Dosing regimens typically provided as twice-daily administration alongside low-dose aspirin.
Shelf life consistent with standard oral tablet formulations, generally two years under recommended storage.
Instructions include recommendations for concomitant aspirin use and warnings about dose limits.
Patient information leaflets detailing potential side effects, contraindications, and administration guidelines provided within packaging.
Prescribed primarily for cardiovascular indications requiring antiplatelet therapy.
No intravenous or alternative systemic dosage forms currently approved for ticagrelor.
Manufactured following Good Manufacturing Practices (GMP) ensuring product consistency and safety.
Formulations designed to optimize bioavailability and rapid onset of action for acute coronary syndrome scenarios.